AU2020251960A1 - Systemic isoxazoline parasiticides for vector-borne and viral disease treatment or prophylaxis - Google Patents

Systemic isoxazoline parasiticides for vector-borne and viral disease treatment or prophylaxis Download PDF

Info

Publication number
AU2020251960A1
AU2020251960A1 AU2020251960A AU2020251960A AU2020251960A1 AU 2020251960 A1 AU2020251960 A1 AU 2020251960A1 AU 2020251960 A AU2020251960 A AU 2020251960A AU 2020251960 A AU2020251960 A AU 2020251960A AU 2020251960 A1 AU2020251960 A1 AU 2020251960A1
Authority
AU
Australia
Prior art keywords
formulation
sufficient
vector
doses
isoxazoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020251960A
Other languages
English (en)
Inventor
Douglas Michael Ackermann
Bobak Robert Azamian
Shawn D. Hickok
Christopher Stivers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tarsus Pharmaceuticals Inc
Original Assignee
Tarsus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tarsus Pharmaceuticals Inc filed Critical Tarsus Pharmaceuticals Inc
Publication of AU2020251960A1 publication Critical patent/AU2020251960A1/en
Priority to AU2026205483A priority Critical patent/AU2026205483A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020251960A 2019-04-04 2020-04-03 Systemic isoxazoline parasiticides for vector-borne and viral disease treatment or prophylaxis Abandoned AU2020251960A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2026205483A AU2026205483A1 (en) 2019-04-04 2026-07-09 Systemic isoxazoline parasiticides for vector-borne and viral disease treatment or prophylaxis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962829573P 2019-04-04 2019-04-04
US62/829,573 2019-04-04
PCT/IB2020/053229 WO2020202111A1 (en) 2019-04-04 2020-04-03 Systemic isoxazoline parasiticides for vector-borne and viral disease treatment or prophylaxis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2026205483A Division AU2026205483A1 (en) 2019-04-04 2026-07-09 Systemic isoxazoline parasiticides for vector-borne and viral disease treatment or prophylaxis

Publications (1)

Publication Number Publication Date
AU2020251960A1 true AU2020251960A1 (en) 2021-11-11

Family

ID=72667108

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020251960A Abandoned AU2020251960A1 (en) 2019-04-04 2020-04-03 Systemic isoxazoline parasiticides for vector-borne and viral disease treatment or prophylaxis
AU2026205483A Pending AU2026205483A1 (en) 2019-04-04 2026-07-09 Systemic isoxazoline parasiticides for vector-borne and viral disease treatment or prophylaxis

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2026205483A Pending AU2026205483A1 (en) 2019-04-04 2026-07-09 Systemic isoxazoline parasiticides for vector-borne and viral disease treatment or prophylaxis

Country Status (11)

Country Link
US (2) US20220160682A1 (cg-RX-API-DMAC7.html)
EP (1) EP3946325A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022527359A (cg-RX-API-DMAC7.html)
KR (1) KR20220054241A (cg-RX-API-DMAC7.html)
CN (1) CN113993518A (cg-RX-API-DMAC7.html)
AU (2) AU2020251960A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021019931A2 (cg-RX-API-DMAC7.html)
CA (1) CA3136042A1 (cg-RX-API-DMAC7.html)
IL (1) IL286914A (cg-RX-API-DMAC7.html)
MX (1) MX2021012188A (cg-RX-API-DMAC7.html)
WO (1) WO2020202111A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170232024A1 (en) 2014-08-04 2017-08-17 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
CN119157876A (zh) 2017-12-15 2024-12-20 塔苏斯制药有限公司 用于治疗睑炎的异恶唑啉驱虫剂制剂和方法
US12502377B2 (en) * 2019-04-04 2025-12-23 Tarsus Pharmaceuticals, Inc. Method of eradicating ticks that attach to humans using lotilaner formulations
CN111265528A (zh) 2020-01-21 2020-06-12 中国人民解放军军事科学院军事医学研究院 法匹拉韦在治疗冠状病毒感染方面的应用
WO2022079496A1 (en) * 2020-10-13 2022-04-21 Menschlich Healthcare Opc Private Limited A pharmaceutical composition of nitazoxanide, albendazole and pyrantel and method thereof
CN112294793B (zh) * 2020-10-21 2022-03-22 青岛海洋生物医药研究院股份有限公司 氯生太尔或其药学上可接受的盐在制备用于预防和/或治疗冠状病毒感染的药物中的应用
WO2022130031A1 (en) * 2020-12-17 2022-06-23 Chander Mohan Negi A pharmaceutical composition of nitazoxanide and mefloquine and method thereof
CN118420621A (zh) * 2021-02-07 2024-08-02 南京知和医药科技有限公司 一种磺酰胺类多环化合物及其制备方法与用途
US20250318529A1 (en) * 2022-05-16 2025-10-16 Syngenta Crop Protection Ag Method for mosquito control
WO2024168149A1 (en) * 2023-02-10 2024-08-15 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and methods for treating blepharitis
US20240366572A1 (en) * 2023-05-07 2024-11-07 Michael Farber Isoxazoline complexes and compositions thereof
US11903962B1 (en) * 2023-05-07 2024-02-20 Michael Farber Isoxazoline complexes and compositions thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI556741B (zh) * 2007-08-17 2016-11-11 英特威特國際股份有限公司 異唑啉組成物及其作為抗寄生蟲藥上的應用
US8313752B2 (en) * 2009-04-14 2012-11-20 Merial Limited Macrocyclic lactone combination compositions, vaccines and methods for producing same
CN110167540A (zh) * 2016-10-31 2019-08-23 斯克利普斯研究所 用于预防媒介传播疾病的传播的方法和组合物
WO2020051106A1 (en) * 2018-09-05 2020-03-12 Zoetis Services Llc Palatable antiparasitic formulations
BR112022000982A2 (pt) * 2019-07-22 2022-03-08 Intervet Int Bv Forma de dosagem veterinária mastigável macia

Also Published As

Publication number Publication date
US20220160682A1 (en) 2022-05-26
JP2022527359A (ja) 2022-06-01
WO2020202111A1 (en) 2020-10-08
CN113993518A (zh) 2022-01-28
AU2026205483A1 (en) 2026-07-30
MX2021012188A (es) 2022-02-11
CA3136042A1 (en) 2020-10-08
EP3946325A1 (en) 2022-02-09
KR20220054241A (ko) 2022-05-02
US20230218584A1 (en) 2023-07-13
IL286914A (en) 2021-10-31
JP2026083151A (ja) 2026-05-19
BR112021019931A2 (pt) 2021-12-07
EP3946325A4 (en) 2022-12-21

Similar Documents

Publication Publication Date Title
US20230218584A1 (en) Systemic isoxazoline parasiticides for vector-borne and viral disease treatment or prophylaxis
ES2417157T3 (es) Composiciones de isoxazolina y su uso como antiparasitarios
CA2966703C (en) Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
US20260108498A1 (en) Method of eradicating ticks that attach to humans using lotilaner formulations
WO2022269042A1 (en) Palatable veterinary compositions
CN110167540A (zh) 用于预防媒介传播疾病的传播的方法和组合物
IL301015A (en) Formulations of anti-viral compounds
US7709534B2 (en) Method of treating strongyloides infections and medicaments therefor
HK40066895A (en) Systemic isoxazoline parasiticides for vector-borne and viral disease treatment or prophylaxis
JP7274479B2 (ja) 寄生虫の寄生を治療するためのモキシデクチンを含有する組成物
RU2279874C9 (ru) Препарат для профилактики и лечения гельминтозов лошадей
KR20150080647A (ko) 말과 말파리 유충을 내부적으로 억제 또는 처리하기 위한 방법
US20230213515A1 (en) Drug and diagnostic combination system to identify and treat single-stranded rna viruses including coronaviruses and monkeypox
RU2823297C1 (ru) Ветеринарный фармацевтический продукт против эктопаразитов собак
US20250204555A1 (en) Feed and methods for controlling intestinal tract parasitic worm infections in mammals
RU2287332C2 (ru) Препарат для профилактики и лечения гельминтозов животных
US11439638B1 (en) Drug and diagnostic combination system to identify and treat single-stranded RNA viruses including coronaviruses
RU2816320C2 (ru) Изоксазолиновые композиции и их применение в качестве противопаразитарных средств
WO2025136126A1 (es) Composición oral en forma de gel bioadhesivo a base de isoxazolina
NZ537760A (en) Worming formulations comprising a macrocyclic lactone and piperonyl butoxide
BG97845A (bg) Медикаментозен премикс
BR122020024991B1 (pt) Uso de isoxazolina

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted